STS | 300-52-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机硫酸及其衍生物
• 英文名称: STS
• 英文别名: sulfuric acid mono-(4-ethyl-1-isobutyl-octyl ester)；Schwefelsaeure-mono-(4-aethyl-1-isobutyl-octylester)；Tetradecyl hydrogen sulfate (ester)；(7-ethyl-2-methylundecan-4-yl) hydrogen sulfate
• CAS: 300-52-7
• 化学式: C₁₄H₃₀O₄S
• 分子量: 294.456
• InChiKey: GROJOWHVXQYQGN-UHFFFAOYSA-N

物化性质

• 熔点：
  199

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  19
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  72
• 氢给体数：
  1
• 氢受体数：
  4

ADMET

吸收、分配和排泄

• 消除途径

在给予静脉注射放射性标记剂量后，大鼠在给药后24小时内尿液中回收了70%的药物。在给药后72小时结束时，从尿液中回收了73.5%的放射性标记物，从粪便中回收了18.2%。

After an intravenously administered radiolabelled dose, 70% of the drug was recovered in the urine of rats within 24 hours post-dosing. At the end of the 72 hour post-dose period, 73.5% of the radiolabel had been recovered from the urine and 18.2% recovered from the faeces.

来源:DrugBank

吸收、分配和排泄

• 分布容积

在人类中，大约75%的注射剂量的放射性标记的3%十四烷基硫酸钠迅速从空的大隐静脉注射部位消失，进入与之相连的血管，并迅速进入小腿的深静脉。在大鼠中，静脉注射放射性标记的十四烷基硫酸钠72小时后，样本组织（肝脏、肾脏、脂肪和骨骼肌）中放射性物质的含量非常低。尽管有一些证据表明注射部位有放射性标记物，但水平可以忽略不计。

In humans, a large proportion (75%) of an injected dose of radiolabelled 3% sodium tetradecyl sulfate rapidly disappeared from the empty varicose vein injection site into communicating blood vessels with rapid entry into the deep veins of the calf. In rats, at 72 hours after intravenous dosing of radiolabelled sodium tetradecyl sulfate, tissue levels of radiolabelled matter found in sample tissues (liver, kidney, lipid and skeletal muscle) were measured as very low. Although there was some evidence of radiolabel associated with the injection site, the levels were negligible.

来源:DrugBank

反应信息

• 作为产物：
  描述：

  7-ethyl-2-methyl-undeca-5,7-dien-4-one 在 硫酸 、 镍 作用下， 生成 STS
  参考文献：
  名称：

  DE706169

  摘要：

  公开号：

文献信息

• Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
  申请人：Rogers D. Robin

  公开号：US20070093462A1

  公开（公告）日：2007-04-26

  Disclosed are ionic liquids and methods of preparing ionic liquid compositions of active pharmaceutical, biological, nutritional, and energetic ingredients. Also disclosed are methods of using the compositions described herein to overcome polymorphism, overcome solubility and delivery problems, to control release rates, add functionality, enhance efficacy (synergy), and improve ease of use and manufacture.

  揭示了离子液体及制备活性药物、生物、营养和能量成分的离子液体组合物的方法。还揭示了利用本文描述的组合物的方法，以克服多型性、克服溶解度和输送问题、控制释放速率、增加功能性、增强功效（协同作用）以及改善易用性和制造工艺。
• [EN] COMPOSITIONS AND PREPARATION METHODS OF LOW MELTING IONIC SALTS OF POORLY- WATER SOLUBLE DRUGS<br/>[FR] COMPOSITIONS ET PROCÉDÉS DE PRÉPARATION DE SELS IONIQUES À BAS POINT DE FUSION DE MÉDICAMENTS FAIBLEMENT HYDROSOLUBLES
  申请人：UNIV MONASH

  公开号：WO2015013772A1

  公开（公告）日：2015-02-05

  The disclosure relates generally to ionic salts, particularly low-melting ionic salts such as ionic liquids, of poorly- water soluble drugs. The disclosure further relates to methods of preparing the ionic salts of poorly-water soluble drugs, lipid formulations comprising them and their use in drug delivery.

  该披露通常涉及离子盐，特别是低熔点离子盐，例如贫水溶性药物的离子液体。该披露进一步涉及制备贫水溶性药物的离子盐的方法，包含它们的脂质配方以及它们在药物递送中的使用。
• Multi-Functional Ionic Liquid Compositions for Overcoming Polymorphism and Imparting Improved Properties for Active Pharmaceutical, Biological, Nutritional, and Energetic Ingredients
  申请人：Rogers Robin D.

  公开号：US20120264605A1

  公开（公告）日：2012-10-18

  Disclosed are ionic liquids and methods of preparing ionic liquid compositions of active pharmaceutical, biological, nutritional, and energetic ingredients. Also disclosed are methods of using the compositions described herein to overcome polymorphism, overcome solubility and delivery problems, to control release rates, add functionality, enhance efficacy (synergy), and improve ease of use and manufacture.

  本发明涉及离子液体和制备含有活性制药、生物、营养和能量成分的离子液体组合物的方法。同时，本发明还涉及使用所述组合物的方法，以克服多晶性、克服溶解度和输送问题、控制释放速率、增加功能、增强功效（协同作用）和改善使用和制造的便利性。
• SECURITY ELEMENT HAVING VOLUME HOLOGRAM AND PRINTED FEATURE
  申请人：BAYER MATERIALSCIENCE AG

  公开号：US20150353485A1

  公开（公告）日：2015-12-10

  The invention relates to a method for producing a security element having a holographic layer in which a hologram is arranged, characterized by at least the following steps: a) providing the holographic layer; b) exposing the holographic layer at least in sections via a master hologram to produce a hologram copy in the holographic layer; e) printing the holographic layer at least in sections with an ink, forming a printed feature, wherein the ink comprises the melt of a dye or a colorless component or a solvent and a dye dissolved therein or a colorless component dissolved therein; d) fixing the exposed holographic layer to produce the hologram in the holographic layer, wherein the printed feature and the hologram are arranged in the holographic layer such that the printed feature and the hologram overlap at least in sections. The invention further relates to a security feature which is produced or can be produced by said method.

  本发明涉及一种制备具有全息层的安全元素的方法，其中全息图案被排列在全息层中，其特征在于至少包括以下步骤：a）提供全息层；b）通过主全息图案至少在部分区域上曝光全息层，以在全息层中制作全息图案副本；e）使用墨水至少在部分区域上印刷全息层，形成印刷特征，其中墨水包括染料或无色成分或溶剂及其溶解的染料或无色成分的熔体；d）固定曝光的全息层，以在全息层中制作全息图案，其中印刷特征和全息图案排列在全息层中，使印刷特征和全息图案至少在部分区域上重叠。本发明还涉及通过该方法制备或可制备的安全特征。
• COMPOSITIONS AND PREPARATION METHODS OF LOW MELTING IONIC SALTS OF POORLY-WATER SOLUBLE DRUGS
  申请人：MW ENCAP LIMITED

  公开号：US20160151503A1

  公开（公告）日：2016-06-02

  The disclosure relates generally to ionic salts, particularly low-melting ionic salts such as ionic liquids, of poorly-water soluble drugs. The disclosure further relates to methods of preparing the ionic salts of poorly-water soluble drugs, lipid formulations comprising them and their use in drug delivery.

  本发明涉及离子盐，特别是低熔点的离子盐，例如离子液体，用于难溶于水的药物。本发明还涉及制备难溶于水的药物的离子盐的方法，包含它们的脂质配方以及它们在药物输送中的使用。